Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol
Maria-Luisa Schubert, Anita Schmitt, Leopold Sellner, Brigitte Neuber, Joachim Kunz, Patrick Wuchter, Alexander Kunz, Ulrike Gern, Birgit Michels, Susanne Hofmann, Angela Hückelhoven-Krauss, Andreas Kulozik, Anthony D. Ho, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt
BMJ Open May 2019, 9 (5) e026644; DOI: 10.1136/bmjopen-2018-026644